Literature DB >> 2666233

Cooperative binding of two antibodies to independent antigens by an Fc-dependent mechanism.

N S Greenspan1, D A Dacek, L J Cooper.   

Abstract

Binding of a murine N-acetylglucosamine (GlcNAc)-specific IgG3 monoclonal antibody to a solid phase expressing GlcNAc determinants and phosphocholine (PC) determinants is enhanced by IgG3, but not IgG2b, PC-specific monoclonal antibody. The cooperative binding requires an intact Fc region on the GlcNAc-specific monoclonal antibody and is hypothesized to result from Fc-Fc association. Although the in vivo relevance of this phenomenon requires further study, intermolecular cooperativity in binding of antibody to multivalent antigens, such as bacterial cell wall antigens, could represent an adaptive mechanism for antibodies expressing low intrinsic affinities for highly repeated epitopes. Furthermore, the ability of antibodies of distinct specificity to participate in cooperative binding offers, at least in principle, new approaches to optimizing antibody targeting.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2666233     DOI: 10.1096/fasebj.3.10.2666233

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

1.  Isothermal titration calorimetry reveals differential binding thermodynamics of variable region-identical antibodies differing in constant region for a univalent ligand.

Authors:  Tarun K Dam; Marcela Torres; C Fred Brewer; Arturo Casadevall
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

2.  Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure.

Authors:  Alena Janda; Arturo Casadevall
Journal:  Mol Immunol       Date:  2010-03-17       Impact factor: 4.407

Review 3.  Cooperative binding by mouse IgG3 antibodies: implications for functional affinity, effector function, and isotype restriction.

Authors:  N S Greenspan; L J Cooper
Journal:  Springer Semin Immunopathol       Date:  1993

4.  Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.

Authors:  Brendan M Giles; Stephanie J Bissel; Jodi K Craigo; Dilhari R Dealmeida; Clayton A Wiley; Terrence M Tumpey; Ted M Ross
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

5.  Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.

Authors:  Justin D Walter; Rachel A Werther; Maria S Polozova; Julie Pohlman; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  J Biol Chem       Date:  2013-02-15       Impact factor: 5.157

6.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Authors:  P J Klasse
Journal:  Adv Biol       Date:  2014-09-09

7.  Global structures of IgG isotypes expressing identical variable regions.

Authors:  Ertan Eryilmaz; Alena Janda; Jungwook Kim; Radames J B Cordero; David Cowburn; Arturo Casadevall
Journal:  Mol Immunol       Date:  2013-08-01       Impact factor: 4.407

8.  Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.

Authors:  Mireille Vankemmelbeke; Richard S McIntosh; Jia Xin Chua; Thomas Kirk; Ian Daniels; Marilena Patsalidou; Robert Moss; Tina Parsons; David Scott; Gemma Harris; Judith M Ramage; Ian Spendlove; Lindy G Durrant
Journal:  Cancer Res       Date:  2020-06-12       Impact factor: 12.701

9.  Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

Authors:  P B Chapman; S D Gillies; A N Houghton; R M Reilly
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

10.  IgG3-antigen complexes are deposited on follicular dendritic cells in the presence of C1q and C3.

Authors:  Lu Zhang; Zhoujie Ding; Birgitta Heyman
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.